Sign in
Enrolling by invitationPhase 2/3

Long-term follow-up after AAVAnc80-hOTOF gene therapy for otoferlin-related hearing loss

Follows people with otoferlin gene hearing loss who already received AAVAnc80-hOTOF gene therapy.

Key facts

Who runs it
Eli Lilly and Company
Where
Boston, Iowa City, and Philadelphia, United StatesSee the 3 sitesAlso in 2 other countries, 2 sites
Registry title
Long Term Follow-up Study of AAVAnc80-hOTOF Gene Therapy
Status
Enrolling by invitation
Phase
Phase 2/3
People taking part
30 people, planned
Started
11 Nov 2024
Expected to end
Apr 2033
Type of study
Observational
Record updated
4 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with hearing loss caused by changes in the otoferlin gene who already received AAVAnc80-hOTOF in the AK-OTOF-101 trial. It follows their safety and hearing over a long time.

Sex
All sexes can join.
Disease stage
Sensorineural hearing loss (inner ear hearing loss) caused by otoferlin gene changes.
Earlier treatment
Must have received AAVAnc80-hOTOF into the inner ear (cochlea) in the AK-OTOF-101 Clinical Trial.
Biomarker or test result
Otoferlin gene mutations.

Main reasons for not taking part

  • Any condition that would stop the person from completing the follow-up exams.
  • Any condition that, in the investigator's opinion, makes the person unfit for the study.

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • Individuals with otoferlin gene-mediated hearing loss who received intracochlear administration of AAVAnc80-hOTOF in the AK-OTOF-101 Clinical Trial
  • Legally authorized representative and/or participant willingness to comply with all study requirements, as evidenced by successful completion of the informed consent process or permission and participant assent process (where appropriate)

Who cannot take part

  • Any condition that would not allow the potential participant to complete follow-up examinations during the course of the study and/or, in the opinion of the Investigator, makes the potential participant unsuitable for the study

Where in United States

Also in 2 other countries, 2 sites

  • Boston Children's HospitalBoston, United StatesEnrolling by invitation
  • University of IowaIowa City, United StatesEnrolling by invitation
  • Children's Hospital of PhiladelphiaPhiladelphia, United StatesEnrolling by invitation

About the trial

What the trial wants to find out

This multi-center, observational, post-intervention long term follow-up (LTFU) study will monitor for safety and efficacy of AAVAnc80-hOTOF in individuals with sensorineural hearing loss due to otoferlin gene mutations who have previously received intracochlear administration of AAVAnc80-hOTOF in the AK-OTOF-101 Clinical Trial.

The group in the trial

  • Study Participants

    Individuals with otoferlin gene-mediated hearing loss who received intracochlear administration of AAVAnc80-hOTOF in the AK-OTOF-101 Clinical Trial

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
An Evaluation of the Long Term Safety and Efficacy of AAVAnc80-hOTOF Gene Therapy in Individuals With Sensorineural Hearing Loss Due to Otoferlin Gene Mutations
Plain-language title
Long-term follow-up after AAVAnc80-hOTOF gene therapy for otoferlin-related hearing lossGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
4 November 2026